Implantable Cardioverter-Defibrillator of Korean Patients in a Single Center Registry
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: The safety and efficacy of implantable cardioverter-defibrillator (ICD) for Korean is unclear. We investigated the clinical characteristics and outcomes of Korean patients undergoing ICD for primary or secondary prevention. Materials and Methods: From October 1999 to December 2016, 396 cases (365 patients) of ICD implantation were performed: Baseline characteristics, procedural findings, and clinical outcome data were collected retrospectively from our ICD registry. The primary outcome was composite of cardiac death, appropriate shock or antitachycardia pacing. Results: Among 365 patients, 91 patients (25.9%) had ICD for primary prevention and 274 patients (75.1%) were for secondary prevention (51.2±17.10 years, male was 80.8%). The median follow-up period was 3.1 years (interquartile range: 1.6–6.0 days). The most prevalent etiology was dilated cardiomyopathy (46.2%) in the primary prevention and idiopathic ventricular tachycardia or fibrillation (24.4%) in the secondary prevention. The primary outcome was noted in 28.6% of the primary prevention and 33.2% of the secondary prevention (P=0.44). The rate of cardiac death was 2.2% in the primary prevention and 1.8% in the secondary prevention (P=1.00). The hospitalization due to heart failure was higher in the primary prevention compared with the secondary prevention (23.1% versus 13.5%, P=0.03). ICD therapy occurred in 134 patients (36.7%). Among them, 60 patients (44.8% of ICD therapy) experienced inappropriate shock. The most common cause of inappropriate shock was atrial fibrillation of flutter (AF/AFL). Conclusion: The clinical efficacy and safety of ICD in Korean is consistent with the data from Western countries.
Abstract
Background and Objectives: The safety and efficacy of implantable cardioverter-defibrillator (ICD) for Korean is unclear. We investigated the clinical characteristics and outcomes of Korean patients undergoing ICD for primary or secondary prevention. Materials and Methods: From October 1999 to December 2016, 396 cases (365 patients) of ICD implantation were performed: Baseline characteristics, procedural findings, and clinical outcome data were collected retrospectively from our ICD registry. The primary outcome was composite of cardiac death, appropriate shock or antitachycardia pacing. Results: Among 365 patients, 91 patients (25.9%) had ICD for primary prevention and 274 patients (75.1%) were for secondary prevention (51.2±17.10 years, male was 80.8%). The median follow-up period was 3.1 years (interquartile range: 1.6–6.0 days). The most prevalent etiology was dilated cardiomyopathy (46.2%) in the primary prevention and idiopathic ventricular tachycardia or fibrillation (24.4%) in the secondary prevention. The primary outcome was noted in 28.6% of the primary prevention and 33.2% of the secondary prevention (P=0.44). The rate of cardiac death was 2.2% in the primary prevention and 1.8% in the secondary prevention (P=1.00). The hospitalization due to heart failure was higher in the primary prevention compared with the secondary prevention (23.1% versus 13.5%, P=0.03). ICD therapy occurred in 134 patients (36.7%). Among them, 60 patients (44.8% of ICD therapy) experienced inappropriate shock. The most common cause of inappropriate shock was atrial fibrillation of flutter (AF/AFL). Conclusion: The clinical efficacy and safety of ICD in Korean is consistent with the data from Western countries.
참고문헌 (22)
- Turakhia M, "Sudden cardiac death: epidemiology, mechanisms, and therapy", Curr Probl Cardiol, 32, pp.501~546 (2007)
- Moss AJ, "Multicenter Automatic Defibrillator Implantation Trial Investigators", N Engl J Med, 335, pp.1933~1940 (1996)
- Antiarrhythmics versus Implantable Defibrillators (AVID)Investigators, "A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias", N Engl J Med, 337, pp.1576~1583 (1997)
- Moss AJ, "Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction", N Engl J Med, 346, pp.877~883 (2002)
- Al-Khatib SM, "Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials", Jama, 309, pp.55~62 (2013)
- Epstein AE, "2012ACCF", AHA, AHA, pp.HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[DOI]
- Epstein AE, "ACC", AHA, American Heart Association task force on practice guidelines (writing committee to revise the ACC, pp.AHA, NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices)developed in collaboration with the American Association for thoracic surgery and society of thoracic surgeons[DOI]
- 엄재선, "Long-Term Prognosis of Patients with an Implantable Cardioverter-Defibrillator in Korea", Yonsei Medical Journal, 58(3), pp.514~520 (2017), 연세대학교의과대학[DOI]
- 박규환, "Effectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic or Non-Ischemic Etiology in Korea", Korean Circulation Journal, 47(1), pp.72~81 (2017), 대한심장학회
- Swerdlow CD, "Advanced ICD troubleshooting:Part I", PACE, 28, pp.1322~1346 (2005)
- Klein RC, "Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial", J Cardiovasc Electrophysiol, 14, pp.940~948 (2003)
- Al-Khatib SM, "Trends in use of implantable cardioverterdefibrillator therapy among patients hospitalized for heart failure:have the previously observed sex and racial disparities changed over time?", Circulation, 125, pp.1094~1101 (2012)
- Schmidt M, "Thirteen-year nationwide trends in use of implantable cardioverter-defibrillators and subsequent longterm survival", Heart rhythm, 12, pp.2018~2027 (2015)
- Curtis LH, "Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death", Jama, 298, pp.1517~1524 (2007)
- Gauri AJ, "Disparities in the use of primary prevention and defibrillator therapy among blacks and women", Am J Med, 119, pp.167 e17~167 e21 (2006)
- Goldenberg I, "Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II", Circulation, 122, pp.1265~1271 (2010)
- Kadish A, "Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy", N Engl J Med, 350, pp.2151~2158 (2004)
- van Welsenes GH, "Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients", Europace, 13, pp.389~394 (2011)
- Daubert JP, "Inappropriate implantable cardioverter-defibrillator shocks in MADIT II : frequency, mechanisms, predictors, and survival impact", J Am Coll Cardiol, 51, pp.1357~1365 (2008)
- Sweeney MO, "Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial", Circulation, 111, pp.2898~2905 (2005)
- Hintringer F, "Inappropriate detection of supraventricular arrhythmias by implantable dual chamber defibrillators: a comparison of four different algorithms", PACE, 24, pp.835~841 (2001)
- Deisenhofer I, "Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study", J Cardiovasc Electrophysiol, 12, pp.134~142 (2001)